Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.42 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28774057 | 0.87 | ACE2 (0.43) | ACE2GPR84FFAR1CA1MAPT | |
| SCHEMBL15412278 | 0.84 | GPR84 (0.44) | ACE2GPR84FFAR1MAPTLCK | |
| SCHEMBL9331686 | 0.84 | GPR84 (0.44) | ACE2GPR84FFAR1MAPTLCK | |
| SCHEMBL29150446 | 0.84 | CA2 (0.39) | ACE2GPR84FFAR1CA1MAPT | |
| SCHEMBL11336656 | 0.83 | CA2 (0.42) | ACE2GPR84FFAR1CA1MAPT | |
| SCHEMBL27998480 | 0.83 | FFAR4 (0.53) | GPR84FFAR1MAPTPPARDFFAR4 | |
| SCHEMBL2346085 | 0.83 | ACE2 (0.40) | ACE2GPR84FFAR1CA1MAPT | |
| SCHEMBL2904335 | 0.83 | FDPS (0.46) | ACE2GPR84FFAR1MAPTLCK | |
| SCHEMBL28527998 | 0.82 | ACE2 (0.42) | ACE2GPR84FFAR1MAPTLCK | |
| SCHEMBL27998386 | 0.82 | FFAR4 (0.56) | GPR84FFAR1MAPTPPARDBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0817621-B1 | PHARMACEUTICAL COMPOSITION FOR TRANSDERMIC DELIVERY | SANOFI SYNTHELABO (FR) | 2001-06-20 | — | — | EP | claimed |
| US-9072676-B2 | Cyclohexyl carbamate compounds as skin and/or hair lightening actives | SYMRISE AG (DE) | 2015-07-07 | — | — | US | disclosed |
| US-20130156710-A1 | CYCLOHEXYL CARBAMATE COMPOUNDS AS SKIN AND/OR HAIR LIGHTENING ACTIVES | SYMRISE AG (DE) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130156710-A1 | CYCLOHEXYL CARBAMATE COMPOUNDS AS SKIN AND/OR HAIR LIGHTENING ACTIVES | CBR1, CYP2A13, CBR3 | ACE2 3762/4885GPR84 722/4885FFAR1 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.